Tamoxifen citrate is indicated to reduce the incidence of breast cancer in women at high risk for breast cancer. This effect was shown in a study of 5 years planned duration with a median follow-up of 4.2 years. Twenty-five percent of the participants received the drug for 5 years. The longer term effects are not known. In this study, there was no impact of tamoxifen on overall or breast cancer-related mortality.
Tamoxifen citrate is indicated for high-risk women.
One first degree relative with a history of breast cancer, two or more benign biopsies, and a history of a breast biopsy showing atypical hyperplasia. At least two first degree relatives with a history of breast cancer, and a personal history of at least one breast biopsy. One first degree relative with a history of breast cancer, two or more benign biopsies, age at first live birth 25 or older, and age at menarche 11 or younger. At least two first degree relatives with a history of breast cancer, and age at first live birth 19 or younger. One first degree relative with a history of breast cancer, and a personal history of a breast biopsy showing atypical hyperplasia.